XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Income Taxes
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

11. Income Taxes

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:

 

 

 

December 31,

 

(in thousands)

 

2023

 

 

2022

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

71,963

 

 

$

66,067

 

Research and development credits

 

 

20,555

 

 

 

15,234

 

Research and development capitalization

 

 

39,867

 

 

 

19,900

 

Stock-based compensation

 

 

12,990

 

 

 

8,725

 

Accrued expense

 

 

2,539

 

 

 

1,190

 

Lease liabilities

 

 

4,715

 

 

 

511

 

Gross deferred tax assets

 

 

152,629

 

 

 

111,627

 

Less: valuation allowance

 

 

(147,616

)

 

 

(111,053

)

Total deferred tax asset

 

 

5,013

 

 

 

574

 

Deferred tax liability

 

 

 

 

 

 

Right-of-use assets

 

 

(4,641

)

 

 

(500

)

Depreciation

 

 

(372

)

 

 

(74

)

Total deferred tax liabilities

 

 

(5,013

)

 

 

(574

)

Net deferred tax assets

 

$

 

 

$

 

 

The deferred tax assets as of December 31, 2023 and 2022, includes capitalized research and development expenses of $39.9 million and $19.9 million, respectively. The Tax Cuts and Jobs Act passed in 2017 included a provision which requires taxpayers to capitalize and amortize U.S. based research development expenses over a period of five years and non-U.S. based research and development expenses over a period of 15 years effective for tax years beginning after December 31, 2021. In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company’s net deferred tax assets as of December 31, 2023 and December 31, 2022. The valuation allowance increased by $36.6 million and $35.7 million during the years ended December 31, 2023 and 2022, respectively.

A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows:

 

 

 

Year ended
December 31,

 

 

 

2023

 

 

2022

 

Federal tax benefit at statutory rate

 

 

(21.0

)%

 

 

(21.0

)%

State tax, net of federal benefit

 

 

(6.6

)

 

 

(6.6

)

Permanent differences

 

 

1.1

 

 

 

0.8

 

Research and development

 

 

(4.4

)

 

 

(3.5

)

Change in valuation allowance

 

 

30.0

 

 

 

30.9

 

Share-based compensation

 

 

0.9

 

 

 

-

 

Other

 

 

-

 

 

 

(0.6

)

 

 

0

%

 

 

0

%

 

The following table summarizes carryforwards of federal and state net operating losses (“NOL”) and research tax credits:

 

 

 

December 31,

 

(in thousands)

 

2023

 

 

2022

 

NOL carryforwards - Federal

 

$

257,976

 

 

$

236,898

 

NOL carryforwards - State

 

 

259,051

 

 

 

237,565

 

Research tax credits - Federal

 

 

20,521

 

 

 

15,201

 

Research tax credits - State

 

 

43

 

 

 

43

 

 

The NOL carryforwards begin expiring in 2036 for federal and Delaware state income tax purposes, however; all federal, Delaware state, and Kansas state NOL carryforwards generated subsequent to January 1, 2018, are able to be carried forward indefinitely. The NOL carryforwards begin expiring in 2037 and 2042 for Tennessee and Massachusetts, respectively. As of December 31, 2023, the Company also had federal and Delaware research and development tax credit carryforwards of $20.5 million and $43 thousand, respectively, that will begin to expire in 2039 and 2031, respectively, unless previously utilized.

The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception. Delaware state NOLs may also be limited.

As of December 31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of operations. Due to NOL and tax credit carry-forwards that remain unutilized, income tax returns for all tax years remain subject to examination by the taxing jurisdictions. The NOL carryforwards remain subject to review until utilized.